Recent Advances in Therapy for Glioblastoma
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Glioblastoma is the most common primary malignant brain tumor in adults and is a challenging disease to treat. The current standard of care includes maximal safe surgical resection, followed by a combination of radiation and chemotherapy with temozolomide. Despite that, recurrence is quite common, and so we continue to search for more effective treatments both for initial therapy and at the time of recurrence. This article will review recent advances in therapy for glioblastoma, including surgery, radiotherapy, cytotoxic chemotherapies, molecularly targeted agents, and immunotherapy; the role of antiangiogenic agents in the treatment of glioblastoma is discussed in a separate article in this issue of the Archives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442 · cited 1×
“Two retrospective studies have found a correlation between activity of the protein kinase B/AKT pathway and erlotinib response in tumors with overexpression of EGFR, although this has not been confirmed prospectively.(14,15)”
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Kirson, E. D., Dbalý, V., Tovaryš, F., Vymazal, J., Soustiel, J. F., Itzhaki, A., Mordechovich, D., Steinberg-Shapira, S., Gurvich, Z., Schneiderman, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702916104 · Cited by 894
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clement, P. M., Frenay, M., Campone, M., Baurain, J.-F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 575
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465 · cited 1×
“Two retrospective studies have found a correlation between activity of the protein kinase B/AKT pathway and erlotinib response in tumors with overexpression of EGFR, although this has not been confirmed prospectively.(14,15)”
MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma
Verma, A. (2006) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(08)70328-4 · Cited by 452
Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L., Wang, Y., Peng, B., Abrey, L. E., Raizer, J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 429
Self-citationPrados, M. D., Chang, S. M., Butowski, N., DeBoer, R., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J., Rabbitt, J., Page, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9639 · Cited by 378
Self-citationGalanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Hardwick, J. S., Reilly, J. F., Loboda, A., Nebozhyn, M., Fantin, V. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0694 · Cited by 358
Reardon, D. A., Egorin, M. J., Quinn, J. A., Rich, J. N., Gururangan, I., Vredenburgh, J. J., Desjardins, A., Sathornsumetee, S., Provenzale, J. M., Herndon, J. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2185 · Cited by 330
Pichlmeier, U., Bink, A., Schackert, G., & Stummer, W. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-052 · Cited by 326
Kunwar, S., Prados, M. D., Chang, S. M., Berger, M. S., Lang, F. F., Piepmeier, J. M., Sampson, J. H., Ram, Z., Gutin, P. H., Gibbons, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1117 · Cited by 325
Self-citationQuinn, J. A., Jiang, S. X., Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Rich, J. N., Gururangan, S., Friedman, A. H., Bigner, D. D., Sampson, J. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8417 · Cited by 316
McGirt, M. J., Than, K. D., Weingart, J. D., Chaichana, K. L., Attenello, F. J., Olivi, A., Laterra, J., Kleinberg, L. R., Grossman, S. A., Brem, H., et al. (2009) · Journal of Neurosurgery · doi:10.3171/2008.5.17557 · Cited by 299
Brown, P. D., Krishnan, S., Sarkaria, J. N., Wu, W., Jaeckle, K. A., Uhm, J. H., Geoffroy, F. J., Arusell, R., Kitange, G., Jenkins, R. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0612 · Cited by 277
Clarke, J. L., Iwamoto, F. M., Sul, J., Panageas, K., Lassman, A. B., DeAngelis, L. M., Hormigo, A., Nolan, C. P., Gavrilovic, I., Karimi, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7944 · Cited by 179
Self-citationCloughesy, T. F., Wen, P. Y., Robins, H. I., Chang, S. M., Groves, M. D., Fink, K. L., Junck, L., Schiff, D., Abrey, L., Gilbert, M. R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2323 · Cited by 154
Self-citationEGFRvIII‐Targeted Vaccination Therapy of Malignant Glioma
Choi, B. D., Archer, G. E., Mitchell, D. A., Heimberger, A. B., McLendon, R. E., Bigner, D. D., & Sampson, J. H. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00318.x · Cited by 148
Salazar, A. Μ., Levy, H. B., Ondra, S., Kende, M., Scherokman, B., Brown, D. S., Mena, H., Martin, N. S., Schwab, K. A., Donovan, D., et al. (1996) · Neurosurgery · doi:10.1227/00006123-199606000-00006 · Cited by 129
Butowski, N. A., Chang, S. M., Junck, L., DeAngelis, L. M., Abrey, L. E., Fink, K., Cloughesy, T. F., Lamborn, K. R., Salazar, A. Μ., & Prados, M. D. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9693-3 · Cited by 116
Self-citationImmunotherapy of malignant brain tumors
Mitchell, D. A., Fecci, P. E., & Sampson, J. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00603.x · Cited by 104
Cell- and peptide-based immunotherapeutic approaches for glioma
Yamanaka, R. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.03.003 · Cited by 78
Chemotherapeutic wafers for High Grade Glioma
Hart, M. G., Grant, R., Garside, R., Rogers, G., Somerville, M., & Stein, K. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007294 · Cited by 61
Inhibiting kinases in malignant gliomas
Chi, A. S., & Wen, P. Y. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.4.473 · Cited by 54
Molecular strategies for the treatment of malignant glioma—genes, viruses, and vaccines
Selznick, L. A., Shamji, M. F., Fecci, P. E., Gromeier, M., Friedman, A. H., & Sampson, J. H. (2008) · Neurosurgical Review · doi:10.1007/s10143-008-0121-0 · Cited by 50
Bevacizumab for Malignant Gliomas
IWAMOTO, F. M., & Fine, H. A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.11 · Cited by 49
Toward Effective Immunotherapy for the Treatment of Malignant Brain Tumors
Mitchell, D. A., & Sampson, J. H. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.04.003 · Cited by 41
Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside
Germano, I. M., & Binello, E. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9869-5 · Cited by 38
Immunotherapy for cancer: promoting innate immunity
Lotfi, R. (2009) · Frontiers in bioscience · doi:10.2741/3280 · Cited by 20
Cited by
Recent advances in the molecular understanding of glioblastoma
Bleeker, F. E., Molenaar, R. J., & Leenstra, S. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0793-0 · Cited by 456
Lai, A., Kharbanda, S., Pope, W. B., Tran, A., Solis, O. E., Peale, F., Forrest, W. F., Pujara, K., Carrillo, J. A., Pandita, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8715 · Cited by 433
Amide proton transfer imaging of adult diffuse gliomas: correlation with histopathological grades
Togao, O., Yoshiura, T., Keupp, J., Hiwatashi, A., Yamashita, K., Kikuchi, K., Suzuki, Y., Suzuki, S. O., Iwaki, T., Hata, N., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not158 · Cited by 392
Glioblastoma multiforme: State of the art and future therapeutics
Harter, D., Wilson, T., & Karajannis, M. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.132138 · Cited by 327
Moravan, M. J., Olschowka, J. A., Williams, J. P., & O'Banion, M. K. (2011) · Radiation Research · doi:10.1667/rr2587.1 · Cited by 163
Metadata
- Authors
- Clarke, J., Butowski, N., & Chang, S.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2010-03-01
- Volume
- 67
- Issue
- 3
- Pages
- 279-83
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2022976025
- Cited by
- 283
- References
- 33
- FWCI
- 12.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.